Hansoh Pharmaceutical Group Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Huijuan Zhong

Chief executive officer

CN¥14.8m

Total compensation

CEO salary percentage	49.6%
CEO tenure	8.8yrs
CEO ownership	n/a
Management average tenure	8.5yrs
Board average tenure	6.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Huijuan Zhong's remuneration changed compared to Hansoh Pharmaceutical Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	CN¥5b
Mar 31 2024	n/a	n/a	CN¥4b
Dec 31 2023	CN¥15m	CN¥7m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥3b
Jun 30 2023	n/a	n/a	CN¥3b
Mar 31 2023	n/a	n/a	CN¥3b
Dec 31 2022	CN¥11m	CN¥5m	CN¥3b
Sep 30 2022	n/a	n/a	CN¥3b
Jun 30 2022	n/a	n/a	CN¥3b
Mar 31 2022	n/a	n/a	CN¥3b
Dec 31 2021	CN¥16m	CN¥8m	CN¥3b

Compensation vs Market: Huijuan's total compensation ($USD2.11M) is below average for companies of similar size in the German market ($USD5.36M).

Compensation vs Earnings: Huijuan's compensation has increased by more than 20% in the past year.

CEO

Huijuan Zhong (63 yo)

8.8yrs

Tenure

CN¥14,807,000

Compensation

Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Huijuan Zhong	Chairlady	8.8yrs	CN¥14.81m	no data
Aifeng Lyu	Executive Director	8.5yrs	CN¥9.39m	0.023% CN¥ 3.5m
Yuan Sun	Executive Director	8.8yrs	CN¥16.63m	0.021% CN¥ 3.1m
Min Hu	VP & CFO	no data	no data	no data
Chih-Hung Lee	Chief of Science Officer	2.4yrs	no data	no data
Chuanhe Xu	Senior Vice President	15.5yrs	no data	no data
Weiyong Sun	Chief Commercial Officer	no data	no data	no data
Shengli Zhong	Joint Company Secretary & Senior VP	6.1yrs	no data	no data
Sze Wai Tam	Joint Company Secretary	less than a year	no data	no data

8.5yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 3KY's management team is seasoned and experienced (8.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Huijuan Zhong	Chairlady	8.8yrs	CN¥14.81m	no data
Aifeng Lyu	Executive Director	8.5yrs	CN¥9.39m	0.023% CN¥ 3.5m
Yuan Sun	Executive Director	8.8yrs	CN¥16.63m	0.021% CN¥ 3.1m
Guoqiang Lin	Independent Non-Executive Director	5.3yrs	CN¥360.00k	no data
Sheung Wai Chan	Independent Non-Executive Director	5.3yrs	CN¥360.00k	no data
Dongtao Yang	Independent Non-Executive Director	5.3yrs	CN¥360.00k	no data

6.9yrs

Average Tenure

65yo

Average Age

Experienced Board: 3KY's board of directors are considered experienced (6.9 years average tenure).

Hansoh Pharmaceutical Group Management

Management criteria checks 3/4

Key information

Recent management updates

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

Now 27% undervalued

Now 21% undervalued

Upcoming dividend of HK$0.14 per share

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Now 21% undervalued

New minor risk - Dividend sustainability

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Investor sentiment improves as stock rises 15%

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

New major risk - Share price stability

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Now 23% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Now 23% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Now 23% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.8% yield

Now 21% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)

Insufficient new directors

Now 20% undervalued after recent price drop

Full year 2022 earnings released

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Investor sentiment improved over the past week

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share

First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of HK$0.09 per share

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10383 tablets"